Experience
Elan Pharmaceuticals
KV Pharmaceuticals (Paradissis)
We assisted our client Elan Pharmaceuticals in obtaining a judgment against Paradissis based on the benefit of the earlier filing date of Elan’s foreign priority application. The subject involved controlled-release pharmaceutical formulation for once-per-day administration.
Elan Pharmaceuticals v. KV Pharmaceuticals (Paradissis), Int. No. 104,617, BPAI, Sprizzo
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.